Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction

NCT: NCT05190978 · RECRUITING

NCT IDNCT05190978
StatusRECRUITING
Start Date2022-10-20
Completion2027-04-30

Brief Summary

Surgical mesh products, particularly acellular dermal matrices (ADM), are now used by the majority of plastic surgeons to assist with the nearly 100,000 prosthetic breast reconstruction procedures in the United States, despite never being approved by Food and Drug Administration (FDA) for this indication. As surgeons transition to placing breast implants above the chest muscle (pre-pectoral), there has been an increasing reliance on these often expensive mesh products without robust evidence to understand their risks and benefits. Our pilot study is a randomized multi-center trial to evaluate surgical mesh assistance in pre-pectoral tissue expander to breast implant reconstruction to address vital questions for women's public health.

Frequently Asked Questions

What is Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction?

Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction is a clinical trial registered under NCT05190978. Current status: RECRUITING.

What is the status of NCT05190978?

The current status of NCT05190978 (Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction) is: RECRUITING.

When did Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction start?

Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction started on 2022-10-20.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.